In 2021, we have continued the research on COVID-19 with contributions in the areas of epidemiological, therapeutics and basic research, including the new HLT platform for the screening of antivirals. Moreover, studies on HIV persistence have focused on tissue reservoirs, with emphasis on the single-cell characterization of the immune microenvironment. In International Health and Tuberculosis, several international projects have been completed (the MyHealth project, the Multibenz clinical trial, framed within the European BERENICE project). On the other hand, research lines such as tuberculosis and helminthes infections have been strengthened, obtaining projects in competitive calls to evaluate new therapeutic schemes. In the Antibiotic Resistance Laboratory, in vitro proof-of-concept testing of HeatShot technology for the prevention of biofilms in the endotracheal tubes of intubated patients in the ICU was carried out. A prototype has also been developed for this purpose.
Group Leader
Benito Almirante Gragera, María José Buzón Gómez
Principal Investigator (PI)
Vicenç Falcó, Joaquín Burgos, Jordi Navarro, María José Buzón, Txell Genescà, Israel Molina, Fernando Salvador, Adrian Sánchez, Núria Serre, Inés Oliveira, Jordi Gómez, Joan Gavaldà, Benito Almirante, Laura Escolà, Òscar Len
Researchers
Adrià Curran, María Jesús Barberà, Maider Arando, Silvina Magnani, Daniel Pieren, Yasmine Baktash, Begoña Triviño, Diana Pou, Marisa Aznar, Raisa Morales, Pepe Santos, Dolors Rodríguez, Núria Fernàndez, Isabel Ruiz, Ibai Los Arcos
PhD Students
Jorge García, Vicente Descalzo, Patricia Alvarez, Paula Suanzes, Sebastian González, Nerea Sánchez, David Perea, Ana Gallego, Cristina Mancebo, Pau Bosch, Juan Espinosa, Estela Muñoz, Marta Palau, Júlia Sellarés, Ester Márquez, Arnau Monforte
Lab Technicians
Joan Rey, Xavier Gomis
Nursing and Technical Staff
Bibiana Planas, Marta Sanchis, Lucía Rodríguez, Claudia Broto, Luis Lòpez, Desideria Martínez, Esperanza Esteban
120
PUBLICATIONS
780
IMPACT FACTOR
6.50
AVERAGE IMPACT FACTOR
SELECTED ARTICLES
Los-Arcos I, Berastegui C, Martin-Gomez MT, Grau S, Campany-Herrero D, Deu M, Sacanell J, Campillo N, Bravo C, Len O
Nebulized micafungin treatment for Scopulariopsis/Microascus tracheobronchitis in lung transplant recipients.
Antimicrob Agents Chemother. 2021 May 18;65(6):e02174-20.
DOI: DOI: 10.1128/AAC.02174-20
IF: 5.191
Grau-Exposito J, Sanchez-Gaona N, Massana N, Suppi M, Astorga-Gamaza A, Perea D, Rosado J, Falco A, Kirkegaard C, Torrella A, Planas B, Navarro J, Suanzes P, Alvarez-Sierra D, Ayora A, Sansano I, Esperalba J, Andres C, Anton A, Ramon Y Cajal S, Almirante B, Pujol-Borrell R, Falco V, Burgos J, Buzon MJ, Genesca M
Peripheral and lung resident memory T cell responses against SARS-CoV-2.
Nat Commun. 2021 May 21;12(1):3010
DOI: DOI: 10.1038/s41467-021-23333-3
IF: 14.919
Sanchez-Montalva A, Salinas C, Sullerio E, Salvador F, Bosch-Nicolau P, Crespillo-Andujar C, Trigo E, Roure S, Valerio L, Espinosa-Pereiro J, Molina I
Risk of Trypanosoma cruzi infection among travellers visiting friends and relatives to continental Latin America.
PLoS Negl Trop Dis. 2021 Jul 2;15(7):e0009528.
DOI: DOI: 10.1371/journal.pntd.0009528
IF: 4.411
Marquez-Algaba E, Pigrau C, Bosch-Nicolau P, Vinado B, Serra-Pladevall J, Almirante B, Burgos J
Risk Factors for Relapse in Acute Bacterial Prostatitis: the Impact of Antibiotic Regimens.
Microbiol Spectr. 2021 Oct 31;9(2):e0053421.
DOI: DOI: 10.1128/Spectrum.00534-21
IF: 7.171
Willekens R, Puig-Asensio M, Suanzes P, Fernandez-Hidalgo N, Larrosa MN, Gonzalez-Lopez JJ, Rodriguez-Pardo D, Pigrau C, Almirante B
Mortality in Staphylococcus aureus bacteraemia remains high despite adherence to quality indicators: secondary analysis of a prospective cohort study
J Infect. 2021 Dec;83(6):656-663
DOI: DOI: 10.1016/j.jinf.2021.10.001
IF: 6.072
Pesquisa operativa contra a desnutrição crônica infantil em Angola (Projeto CRESCER)
Principal Investigator: Israel Molina Romero
Agency: European Comission
Funding: 3,574,755.509 €
Period: 2021-2025
Charting SARS-CoV-2 entry factors in human tissues
Principal Investigator: Meritxell Genescà Ferrer
Agency: Fundació La Marató de TV3
Funding: 61,250 €
Period: 2021-2024
Multicentre Controlled Open Randomized Clinical Trial to assess efficacy and safety of an anti-TB drug combination based on high dose Rifampicin, high dose Moxifloxacin and Linezolid for DS smear positive pulmonary TB during the first 8 weeks of treatment
Principal Investigator: Adrián Sánchez Montalvá
Agency: Instituto de Salud Carlos III
Funding: 187,550 €
Period: 2021-2023
Impact of early treatment during acute HIV infection on the metabolism of reservoir and immune effector cells: Identification of new targets to reduce persistent HIV
Principal Investigator: Jordi Navarro Mercadé
Agency: Instituto de Salud Carlos III
Funding: 87,120 €
Period: 2021-2023
Evaluación de la eficacia y seguridad de ivermectina en dosis única para el tratamiento de la estrongiloidiasis no complicada en pacientes inmunodeprimidos
Principal Investigator: Fernando Salvador Velez
Agency: Sdad Española Enferm Infec Microb Clínica SEIMC
Funding: 65,084.91 €
Period: 2021-2023
System for thermotherapy treatment or prevention of antimicrobial resistant or biofilm infections
Priority Number: 62/301,946.2016
Priority Date: 01/03/2016
Applicants: VHIR, IBEC, ICREA
Biofilm preventing system for respiratory medical devices
Priority Number: U202032239
Priority Date: 2020
Applicants: VHIR
Bi-functionalized nanoparticles, process for its preparation and uses thereof.
Priority Number: P5004PC00
Priority Date: 02.08.2019
Applicants: ICREA, VHIR, ICN2
Antiviral Agent
Priority Number: P5864EP00
Priority Date: 23.06.2021
Applicants: VHIR, IMIM
